SR
Therapeutic Areas
IMUNON Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMNN-001 (TheraPlas™-IL-12) | Advanced Ovarian Cancer (Epithelial Ovarian Cancer) | Phase 2 |
| PlaCCine Platform | Infectious Diseases (e.g., SARS-CoV-2) & Cancer | Preclinical |
Leadership Team at IMUNON
DV
Douglas V. Faller
Chief Medical Officer
KA
Khursheed Anwer
Executive Vice President and Chief Science Officer
JW
Jeffrey W. Church
Interim Chief Financial Officer
SH
Sebastien Hazard
Executive Vice President & Chief Medical Officer
MH
Michael H. Tardugno
Board of Directors
FJ
Frederick J. Fritz
Board of Directors
DB
Donald Braun
Board of Directors
CP
Christine Pellizzari
Board of Directors
JE
James E. Dentzer
Board of Directors